📈NYSE Texas Proposes Rule Change for Connectivity Fee Schedule
The Securities and Exchange Commission has published a notice regarding NYSE Texas, Inc.'s proposed amendments to its Connectivity Fee Schedule. The changes aim to update third-party system access and data feed costs, providing additional options for users while maintaining fees for existing services. The amendments reflect evolving market demands and competitive considerations among users.
Learn More📊Proposed 2025 CAT Fees and Their Impact on Industry Members
The SEC has published a notice regarding the proposed rule change by Nasdaq GEMX to establish fees for Industry Members associated with the Consolidated Audit Trail (CAT). The fees aim to cover operational costs under the CAT NMS Plan for the latter half of 2025, impacting market participants significantly.
Learn More⚖️Postponement of MDI Investigation Determination by Commerce
The U.S. Department of Commerce has postponed the preliminary determination in its investigation of methylene diphenyl diisocyanate imports from China. This extension allows further evaluation of initial responses from respondents. The new deadline for the preliminary determination is set for September 10, 2025. Stakeholders must remain aware of potential implications for trade practices and regulatory compliance.
Learn More📄OMB Issues July 2025 Cumulative Report on Rescissions Proposals
Pursuant to the Congressional Budget and Impoundment Control Act of 1974, OMB is issuing a monthly cumulative report (for July 2025) from the Director detailing the status of rescission proposals that were previously transmitted to the Congress on June 3, 2025.
Learn More💊FDA Regulatory Review Period for HEMGENIX Patent Extension
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for HEMGENIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.
Learn More📈SEC Proposes New Hosted Solutions Program for Small Retail Brokers
The SEC has issued a notice regarding a proposed rule change from Cboe BZX Exchange to introduce a Small Retail Broker Hosted Solutions Program. This program aims to provide fee waivers and updated eligibility requirements for small retail brokers, facilitating better access to market data for retail investors and competing with other exchanges.
Learn More📊Proposed Fee Waivers for Small Retail Brokers’ Data Access
The Cboe BYX Exchange proposes a new program to incentivize small retail brokers through fee waivers and enhanced data access, allowing brokers to provide services to retail investors at lower costs. By adjusting eligibility requirements for existing data programs, the Exchange aims to increase competition and broaden access to market information.
Learn More🗓️IRS Notice
In the Federal Register that was originally published on June 11, 2025, the Designated Federal Officer signing this document is being changed to John A. Lipold. All other meeting details remain unchanged. This meeting will be held as a virtual video conference via the Microsoft Teams platform.
Learn More📈SEC Notice on Silver Point Specialty Credit Fund Exemption Application
The SEC has issued a notice regarding an application by Silver Point Specialty Credit Fund Management for an exemption under the Investment Company Act. This exemption would allow closed-end investment companies to issue various classes of shares with differing sales loads and fees, enhancing their financing options. Hearing requests on the application are open until August 4, 2025.
Learn More💊FDA Announces Regulatory Review Period for IMDELLTRA Patent Extension
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMDELLTRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.
Learn More